OPKO HEALTH, INC. reported second-quarter 2026 results with revenue of $163.6M, a narrower net loss of $8.4M versus a $148.4M loss a year earlier, and diluted loss per share of $(0.01), improving from $(0.19) in the year-ago quarter.
Financial Highlights
- Revenue was $163.6M for Q2 2026, compared with $156.8M in the prior-year quarter; YoY change 4.3%.
- Net income was a loss of $8.4M for Q2 2026, versus a loss of $148.4M in the prior-year quarter.
- Diluted EPS was a loss of $(0.01) for Q2 2026, versus $(0.19) in the prior-year quarter.
Business Highlights
- Revenue mix shifted as services revenue declined about 28% year-over-year following an oncology diagnostics divestiture; product and IP revenues partially offset the decline.
- Commercial momentum for NGENLA® continues, now approved in more than 50 markets with growing royalties (NGENLA royalties $12.8M year-to-date), indicating traction in global commercialization.
- Rayaldee performance improved, with Q2 sales of $8.1M and year-to-date sales of $14.4M, supported by expanded commercialization in Europe and China through partners.
- Operational footprint and R&D activities continue across Spain, Ireland, Chile and Mexico, with early-stage pipeline development through ModeX.
- Strategic transactions included an amendment with Nicoya that adds a 15% equity stake and expanded Rayaldee Greater China rights, intended to enhance long-term upside.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.